CCG-203971
CAY-15075-5 5 mg
Data Sheet: 
SDS:
SDS:
CAS
1443437-74-8
Formulation
A crystalline solid
Purity
≥90%
MW
408,9
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
Signaling through small G proteins of the RhoA subfamily, including RhoC, induces actin-regulated cytosolic-to-nuclear translocation of the oncogene product megakaryoblastic leukemia 1 (MKL1), which binds to serum response factor (SRF).{15012} The MKL1/SRF complex, in turn, activates the transcription of serum response element (SRE) regulated genes, stimulating cell migration, a process that is central to metastasis.{15012} CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50 = 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM.{25536} This compound also inhibits PC-3 cell migration (IC50 = 4.2 μM), as determined by a scratch wound assay.{25536} CCG-203971 causes no cytotoxicity when evaluated by WST-1 assay.{25536} It is well tolerated in normal mice up to doses of 100 mg/kg given intraperitoneally over five days.{25536}
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
